Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Receivables - Net (2016 - 2025)

Historic Receivables - Net for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to $294514.0.

  • China Pharma Holdings' Receivables - Net fell 9793.6% to $294514.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $294514.0, marking a year-over-year decrease of 9793.6%. This contributed to the annual value of $13.8 million for FY2024, which is 329.73% down from last year.
  • China Pharma Holdings' Receivables - Net amounted to $294514.0 in Q3 2025, which was down 9793.6% from $13.9 million recorded in Q2 2025.
  • China Pharma Holdings' Receivables - Net's 5-year high stood at $14.3 million during Q4 2023, with a 5-year trough of $275244.0 in Q2 2023.
  • Moreover, its 5-year median value for Receivables - Net was $545094.0 (2021), whereas its average is $5.4 million.
  • Its Receivables - Net has fluctuated over the past 5 years, first soared by 497220.03% in 2024, then tumbled by 9793.6% in 2025.
  • Quarter analysis of 5 years shows China Pharma Holdings' Receivables - Net stood at $714475.0 in 2021, then crashed by 41.0% to $421531.0 in 2022, then surged by 3290.15% to $14.3 million in 2023, then dropped by 3.3% to $13.8 million in 2024, then plummeted by 97.87% to $294514.0 in 2025.
  • Its Receivables - Net stands at $294514.0 for Q3 2025, versus $13.9 million for Q2 2025 and $13.9 million for Q1 2025.